MONTREAL – September 23, 2019 – SoundBite Medical Solutions Inc. (SBMS) today announced the appointments of William L Hunter, MD, Azin Parhizgar, PhD and Rick Geoffrion to the Board of Directors.
“We are extremely excited and pleased to welcome these three medical device industry veterans. Their deep business expertise in Interventional Cardiology will be invaluable to SoundBite and we are confident that their broad experiences with both emerging and multinational healthcare companies will significantly strengthen and extend the reach of our Board,” said Dr. Francis Bellido, President and Chief Executive Officer of SoundBite Medical. “We are also very pleased that Dr. Hunter has accepted to act as Chairman of the Board,” added Dr. Bellido.
Bill Hunter, MD is Founder, President & Chief Executive Officer of Canary Medical. Dr. Hunter is a senior healthcare leader with over 20 years’ experience as a public company CEO in both medical device and specialty pharmaceutical companies. He has spent his career examining ways to make medical devices “smarter” and more effective through the use of technologies borrowed from outside the industry such as pharmaceutical coatings, surface modification and sensor technologies. As an inventor with over 200 patents and patent applications to his name, he has been involved in the discovery and development of the TAXUS® Drug-Eluting Coronary Stent, the Zilver PTX Peripheral Drug-Eluting Stent, and the Quill barbed wound closure device; combined these products have been used in over 40 million patients and recorded revenues of over $25 billion. Dr. Hunter was Co-Founder of Angiotech Pharmaceuticals and served as its President and Chief Executive Officer from 1997-2011. He was also President & Chief Executive Officer of Correvio (formerly Cardiome).
Azin Parhizgar, PhD is an experienced and highly successful medical device industry Executive and serial entrepreneur currently serving on a number of industry and academic board positions. Most recently she served as President and Chief Executive Officer of Claret Medical, Inc., an embolic protection company, transforming the company from an early stage venture-backed company to a successful revenue-stage company, and leading to the company’s sale to Boston Scientific Corporation. Her previous experiences include serving as Chief Operating Officer of Conor Medsystems Inc., Executive Vice President of Clinical, Regulatory, and Quality Engineering at Arterial Vascular Engineering (AVE), and management positions at J&J, CR Bard, and Summit technologies. Dr. Parhizgar has served as an advisor to emerging medical device technology companies including several Board of Directors and Scientific Advisory Board positions throughout her career.
Rick Geoffrion currently serves as the President and Chief Executive Officer of Cyrano Therapeutics, a venture-backed private company that has developed a treatment to restore function in patients experiencing a chronic loss of smell and flavor. He is a member of the Executive Committee and the Board of the Medical Device Innovation Consortium (MDIC). Rick has more than 35 years of management experience in the medical device industry with over 30 years focus in the cardiovascular device space. Prior to Cyrano, he was the President and CEO of Mitralign, which sold to Edwards Lifesciences in March of 2019. Prior to Mitralign, Mr. Geoffrion served as the President and CEO of Accelerated Technologies, a medical device incubator. In this role he co-founded and led the recapitalization and redirection of six cardiovascular medical device companies (Impella which was acquired by Abiomed, Pathway Medical which was acquired by Bayer, CircuLite which was acquired by Heartware, FlowMedica which was acquired by Angiodynamics, Mitralign and X-Cell). Mr. Geoffrion served on the Accel Board of Directors at ADVAMED from 2013 – 2019 and has also held executive positions at Invatec, PercuSurge, Boston Scientific, SciMed Life Systems, Olympus and Baxter.
SoundBite Medical Solutions Inc. is developing a proprietary shock wave platform technology to address significant unmet clinical needs in interventional vascular and treatment. Through an elegant combination of hardware and software, it can, in a controlled manner, deliver high amplitude shock wave pulses through guidewires and other interventional tools, to specifically address highly calcified and fibrotic tissue, in the diseased cardio vascular walls, resulting in restoring blood passage while leaving healthy, elastic arterial tissue unharmed.
For information on SoundBite Medical Solutions, please contact Mandy Di Lazzaro, Director, HR & Communications (email@example.com) or Dr. Francis Bellido, CEO (firstname.lastname@example.org), SoundBite Medical Solutions, 2300 Alfred Nobel, Technoparc St-Laurent, Montreal Québec H4S 2A4.
For additional information visit www.soundbitemedical.com
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.